TELCON RF PHARMACEUTICAL. Inc. (KOSDAQ:200230)
South Korea · Delayed Price · Currency is KRW 2,170.00
+10.00 (0.46%)
Aug 24, 2026, 3:30 PM KST
TELCON RF PHARMACEUTICAL. Financials Overview
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 42,878 | 43,162 | 37,865 | 36,307 | 27,830 | 37,841 |
Revenue Growth | 7.70% | 13.99% | 4.29% | 30.46% | -26.46% | 14.18% |
Gross Profit Gross Profit Growth | 10,440 | 10,120 | 10,237 | 9,507 | 5,563 | 9,061 |
Operating Income Operating Income Growth | 795 | 718.59 | -70.55 | 965.32 | -4,063 | -4,563 |
Net Income Net Income Growth | -8,298 | -11,456 | -26,320 | 13,906 | -42,084 | -23,098 |
Earnings Per Share EPS Growth | -1480.92 | -2390.00 | -7420.00 | 3417.07 | -13223.92 | -8764.33 |
EPS Growth | - | - | - | - | - | - |
| Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
RF Business Division RF Business Division Growth | 9,982 | 12,770 | 11,811 | 12,401 | 26,433 |
Pharmaceutical/Bio Business Division Pharmaceutical/Bio Business Division Growth | 34,723 | 26,871 | 25,893 | 16,487 | 15,232 |
Elimination of Internal Transactions, Etc. Elimination of Internal Transactions, Etc. Growth | -1,543 | -1,775 | -1,397 | -1,058 | -3,825 |
Total Total Growth | 43,162 | 37,865 | 36,307 | 27,830 | 37,841 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 30,842 | 32,125 | 10,037 | 10,519 | 9,734 | 23,195 |
Total Debt Total Debt Growth | 39,823 | 34,268 | 55,691 | 27,423 | 30,275 | 55,936 |
Net Cash (Debt) Net Cash Growth | -8,981 | -2,143 | -45,654 | -16,904 | -20,542 | -32,741 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share Net Cash Per Share Growth | -1601.14 | -446.86 | -12869.32 | -3767.91 | -4985.94 | -12423.17 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 929.32 | 1,667 | 1,219 | -1,135 | -2,093 | -358.56 |
Capital Expenditures CapEx Growth | -524.63 | -319.81 | -4,968 | -3,820 | -819.43 | -2,254 |
Free Cash Flow Free Cash Flow Growth | 404.69 | 1,347 | -3,749 | -4,954 | -2,912 | -2,613 |
Free Cash Flow Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 24.35% | 23.45% | 27.03% | 26.19% | 19.99% | 23.95% |
Operating Margin | 1.85% | 1.67% | -0.19% | 2.66% | -14.60% | -12.06% |
Pretax Margin | -19.35% | -26.48% | -69.98% | 38.42% | -151.34% | -60.45% |
Profit Margin | -19.35% | -26.54% | -69.51% | 38.30% | -151.22% | -61.04% |
FCF Margin | 0.94% | 3.12% | -9.90% | -13.64% | -10.46% | -6.90% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 25, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | - | - | - | 7.02 | - | - |
P/FCF Ratio | 36.74 | 46.65 | - | - | - | - |
PS Ratio | 0.35 | 1.46 | 1.86 | 2.69 | 3.96 | 6.76 |